Zynex Financial Restructuring Puts Company on Path to Long-Term Success
Rhea-AI Summary
Zynex (NASDAQ: ZYXI) announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring on December 16, 2025, supported by new financing from the company’s lenders. The company said operations will continue as usual with no impact to patients, customers, or employees. Management described the financing as a demonstration of lender confidence and said the restructuring positions Zynex for long-term success. The company provided a public case website for more information: https://dm.epiq11.com/Zynex.
Positive
- New lender financing secured to support restructuring
- Operations continue with no impact to patients, customers, or employees
Negative
- Voluntary Chapter 11 filing initiated on December 16, 2025
News Market Reaction
On the day this news was published, ZYXI declined 48.60%, reflecting a significant negative market reaction. Argus tracked a trough of -42.2% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $19M from the company's valuation, bringing the market cap to $20M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
Pre-announcement, ZYXI was down 10.58% while peers showed mixed moves (e.g., SNYR +6.52%, EDAP +12.97%, several others modestly down), indicating stock-specific pressure rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Q3 2025 earnings | Negative | -0.5% | Sharp revenue decline, large net loss and impairment, liquidity concerns disclosed. |
| Nov 14 | Strategic review | Negative | -27.0% | Engaged advisor and formed Special Committee to evaluate capital and restructuring options. |
| Nov 14 | Earnings call setup | Neutral | -27.0% | Scheduled Q3 2025 earnings call and webcast logistics announcement. |
| Oct 14 | Board appointment | Positive | +0.7% | Appointment of Bret Wise as director and Audit Committee Chair to bolster oversight. |
| Aug 18 | Leadership changes | Positive | +0.0% | New CEO and senior leadership team appointments to drive future strategy. |
Recent negative financial and restructuring developments have generally coincided with negative price reactions, while governance and leadership updates saw flat-to-slightly-positive moves.
Over the last few months, Zynex has shifted from leadership renewal toward financial stress and restructuring. In August 2025, a new CEO and leadership team were announced, followed by the appointment of Bret Wise as Audit Committee Chair on October 14, 2025. By November, the company disclosed going-concern doubts, delayed its 10-Q, and reported Q3 2025 results with sharply lower revenue and significant losses while exploring strategic alternatives. The current Chapter 11 filing follows this progression from governance changes to liquidity challenges and formal restructuring discussions.
Market Pulse Summary
The stock dropped -48.6% in the session following this news. A negative reaction despite management’s emphasis on long-term success fits the pattern of growing concern seen since Q3 2025 results and going‑concern disclosures. The move into Chapter 11 formalized restructuring risks that had been signaled through delayed filings, missed interest payments discussions, and strategic reviews. Past governance and leadership updates did little to offset financial stress, so equity holders faced heightened uncertainty as the process advanced.
Key Terms
chapter 11 regulatory
AI-generated analysis. Not financial advice.
"Today we take the next step in creating a new future for Zynex," said Steven Dyson, Chief Executive Officer. "This financing demonstrates the confidence our lenders have in our business and the extensive positive changes we have made in recent months. Paired with our renewed commitment to the highest integrity in our business practices, a financial restructuring puts Zynex on the path to long-term success."
Zynex operations will continue as usual with no impact to patients, customers, or employees.
Dyson added, "We look forward to sharing our progress as we fulfill our mission to improve the quality of life for patients suffering from debilitating pain."
For more information, please visit Zynex's case website: https://dm.epiq11.com/Zynex.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to strategies and objectives for future operations; potential outcomes of the evaluation of the strategic alternatives by the Special Committee; and other similar statements.
Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, our ability to identify and complete a transaction as a result of the strategic alternative process; our ability to raise capital or otherwise improve our liquidity position and continue as a going concern; the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; the outcome of the Tricare payment suspension; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, market conditions; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.
These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Vikram Bajaj, CFO
ir@zynex.com
Media Relations Contact:
Britt Logan DiGiulio
media@zynex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-financial-restructuring-puts-company-on-path-to-long-term-success-302643212.html
SOURCE Zynex, Inc.
FAQ
Why did Zynex (ZYXI) enter Chapter 11 on December 16, 2025?
Will Zynex (ZYXI) continue normal operations during the Chapter 11 process?
Did Zynex (ZYXI) secure financing with its Chapter 11 filing?
Where can investors find official documents about Zynex's Chapter 11 case?
What did Zynex management say about the restructuring's purpose for ZYXI shareholders?
Does the December 16, 2025 announcement indicate any immediate change to patient services from Zynex (ZYXI)?
